- Developing replication stress biomarkers, suitable for clinical use, to help progress inhibitors of the replication stress response to the clinic.
- Understanding the mechanisms and consequences of oncogene-induced nuclear changes to establish its role in cancer initiation and development.
- Target the ‘undruggable’ cancer master regulator c-Myc, using our novel target degradation technology, to develop compounds with pan-cancer treatment potential.
- Establishing the anti-cancer mechanisms of CDK4/6 and CDK7 inhibitors, to broaden their clinal use and limit resistance.
- Establish if targeted degradation of the CDK4/6-cyclinD complex elicits better anti-cancer efficacy than inhibition, to develop better ways of targeting CDK activity in cancer treatment.
- Investigate tolerance mechanisms to oncogene-induced replication stress downstream of the essential checkpoint protein kinases ATR, CHK1 and WEE1, to identify cancer specific vulnerabilities
Got questions? Get in touch.
Contact us if you have any questions about the de Bruin Lab.
de Bruin Lab
Click to email. r.debruin@ucl.ac.uk